In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of developing breast and ovarian cancer due to the presence of a pathogenic variant in either of these genes. These pathways are aimed at educating high-risk subjects on programs targeted toward early diagnosis and cancer risk reduction.
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.
GENUARDI, Maurizio;MARCHETTI, PAOLO;NORMANNO, Nicola;PASINI, Barbara;RUSSO, Antonio Fabio;
2016-01-01
Abstract
In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of developing breast and ovarian cancer due to the presence of a pathogenic variant in either of these genes. These pathways are aimed at educating high-risk subjects on programs targeted toward early diagnosis and cancer risk reduction.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2016_Pinto_Future oncology.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
1.67 MB
Formato
Adobe PDF
|
1.67 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
